Thermo Fisher introduces cell therapy workflow media

By The Science Advisory Board staff writers

January 27, 2021 -- Thermo Fisher Scientific has launched a new medium of the first human T lymphocytes (T cells) specifically designed for allogeneic cell therapy workflows.

The Gibco CTS OpTmizer Pro Serum Free Media (SFM) targets the metabolism of healthy donor cells, making it well-suited for use in the production of allogeneic, off-the-shelf cell therapies. The serum free media is compatible with automated and longer workflows and is suited for a closed system. SFM enhances donor T-cell proliferation, maintains central memory T cells further into expansion, and delays effector differentiation of healthy donor T cells, according to the company.

Thermo Fisher closes Henogen acquisition
Thermo Fisher Scientific has closed its acquisition of Groupe Novasep's Henogen, a viral vector manufacturing business in Belgium, for approximately 725 million...
Thermo Fisher subsidizes more sequencers for global coronavirus research
Thermo Fisher Scientific is expanding a global SARS-CoV-2 program that provides its next-generation sequencers at subsidized prices to help analyze new...
Thermo Fisher launches managed equipment plan
Thermo Fisher Scientific has launched a new subscription-based program called Managed Equipment Solutions that combines instrument and equipment sales...
Thermo Fisher acquires Phitonex
Thermo Fisher Scientific has completed its acquisition of Phitonex, a North Carolina-based company that has created a spectral dye platform for high-resolution...
Thermo Fisher expands plasmid manufacturing capabilities
Thermo Fisher Scientific announced it will build a new plasmid DNA manufacturing facility in Carlsbad, CA.

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter